WT1 and acute myeloid leukemia: Its prognostic impact on AML is consistent across different study groups, and our institution has used WT1 expression for a long time [31,32,33,34,35,36,37], even though current recommendations do not favorably support the use of WT1 for MRD assessment in this era of novel technologies [18,20].